RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.

被引：0
|
作者：
Spigel, David R.
Paz-Ares, Luis G.
Chen, Yuanbin
Jove, Maria
Juan-Vidal, Oscar
Rich, Patricia
Hayes, Theresa M.
Calderon, M. Vanesa Gutierrez
Caro, Reyes Bernabe
Navarro, Alejandro
Dowlati, Afshin
Zhang, Bin
Moore, Yan
Wang, Haofei Tiffany
Kokhreidze, Jaba
Nazarenko, Natalya
Aix, Santiago Ponce
Bunn, Paul
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Hosp Univ 12 Octubre, Madrid, Spain
[3] Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA
[4] Inst Catala Oncol, Barcelona, Spain
[5] Hosp Univ & Politecn La Fe, Valencia, Spain
[6] Canc Treatment Ctr Amer, Atalanta, GA USA
[7] South West Healthcare, Warrnambool, Vic, Australia
[8] Hosp Reg Univ Malaga, Malaga, Spain
[9] Hosp Univ Virgen Del Rocio, Seville, Spain
[10] Hosp Univ Vall dHebron, Barcelona, Spain
[11] Case Western Reserve Univ, Cleveland, OH 44106 USA
[12] Univ Colorado, Denver, CO 80202 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9069
引用
收藏
页数：2
相关论文
共 36 条
  • [21] First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study (vol 389, pg 917, 2017)
    Soria, J-C
    Tan, D. S. W.
    Chiari, R.
    LANCET, 2017, 389 (10072): : 908 - 908
  • [22] A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.
    Huang, Dingzhi
    Wang, Ziping
    Yu, Xinmin
    Cheng, Ying
    Wang, Jie
    Fan, Yun
    Ma, Zhiyong
    Shi, Jianhua
    Yu, Yan
    Hu, Yi
    Song, James
    Xia, Fan
    Shen, Zhirong
    Zhang, Yun
    Xu, Yingying
    Condon, Carrie
    Shi, Fangniu
    Zhou, Yunfei
    Pirzkall, Andrea
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)
    Peters, Solange
    Champiat, Stephane
    Yoshida, Tatsuya
    Dorleacq, Nicolas
    Ma, Yiyuan
    Geng, Lijiang
    Leal, Ticiana
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials
    Li, Zhi-Qiang
    Yan, Hai-Cui
    Gu, Jing-Jing
    Yang, Yong-Liang
    Zhang, Ming-Kui
    Fang, Xin-Jian
    PHARMACOLOGICAL RESEARCH, 2020, 160
  • [25] Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02
    Levy, Benjamin Philip
    Paz-Ares, Luis G.
    Su, Wu-Chou
    Herbert, Scott M.
    Yang, Tsung-Ying
    Tolcher, Anthony W.
    Lou, Yanyan
    Zenke, Yoshitaka
    Cortinovis, Diego Luigi
    Felip, Enriqueta
    Domine, Manuel, Sr.
    Leventakos, Konstantinos
    Calvo, Emiliano
    Horiike, Atsushi
    Pan, Edward
    Lin, Daisy
    Jia, Xiaoyu
    Basak, Priyanka
    Chisamore, Michael Jon
    Goto, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab plus tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)
    Dziadziuszko, R.
    Ahn, M-J.
    Kelly, K. A.
    Popat, S.
    Wakelee, H.
    Baird, A-M.
    Rooney, I. A.
    Afshari, M.
    Yao, E. S.
    Zhang, Z.
    Kuriki, H.
    Patil, N. S.
    Wen, X.
    Bradley, J. D.
    ANNALS OF ONCOLOGY, 2021, 32 : S947 - S948
  • [27] An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial
    Gelsomino, F.
    Tiseo, M.
    Boni, L.
    Cavanna, L.
    Camerini, A.
    Chiari, R.
    Verusio, C.
    Tognetto, M.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
    Owonikoko, T. K.
    Kim, H. R.
    Govindan, R.
    Ready, N.
    Reck, M.
    Peters, S.
    Dakhil, S. R.
    Navarro, A.
    Rodriguez-Cid, J.
    Schenker, M.
    Lee, J. S.
    Gutierrez, V.
    Percent, I.
    Morgensztern, D.
    Fairchild, J.
    Baudelet, C.
    Park, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 77 - 77
  • [29] First-line (1L) nivolumab (N) plus ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN
    Kuon, J. B.
    Von der Heyde, E.
    Sadjadian, P.
    Bischoff, M.
    Hassler, A.
    Althoff, A.
    Wilop, S.
    Behringer, D. M.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Ziske, C.
    Groschek, M.
    Laack, H-E.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S852 - S852
  • [30] MYSTIC - A Phase III, randomized, open-label study of Durvalumab (MED14736) in combination with Tremelimumab or Durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced stage IV non small cell lung cancer (aNSCLC): A German update
    von Pawel, J.
    Fischer, J.
    Alt, J.
    Rittmeyer, A.
    Wehler, T.
    Laack, E.
    Griesinger, F.
    Schneider, C. P.
    Panse, J.
    Dieing, A.
    Rawluk, J.
    Serke, M.
    Kropf-Sanchen, C.
    Lerchenmueller, C.
    Bohnet, S.
    Bischoff, H.
    Nusch, A.
    de Wit, M.
    Rupprecht, M.
    Alt, A.
    McIntosh, S.
    Rizvi, N. A.
    Seggewiss-Bernhardt, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 87 - 87
1234